Pharma Mar (PHMMF) Given Consensus Rating of “Strong Buy” by Analysts

Shares of Pharma Mar (NASDAQ:PHMMF) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that cover the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy rating.

Zacks has also given Pharma Mar an industry rank of 123 out of 265 based on the ratings given to related companies.

Separately, Zacks Investment Research downgraded shares of Pharma Mar from a “hold” rating to a “sell” rating in a report on Tuesday, April 4th.

WARNING: “Pharma Mar (PHMMF) Given Consensus Rating of “Strong Buy” by Analysts” was reported by BNB Daily and is the sole property of of BNB Daily. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.baseball-news-blog.com/2017/08/19/pharma-mar-phmmf-given-consensus-rating-of-strong-buy-by-analysts-updated-updated.html.

Shares of Pharma Mar (PHMMF) traded down 0.23% on Friday, reaching $4.43. 3,058 shares of the company’s stock were exchanged. Pharma Mar has a 1-year low of $2.40 and a 1-year high of $4.80. The stock’s 50-day moving average price is $4.47 and its 200-day moving average price is $3.76. The company’s market capitalization is $979.00 million.

Get a free copy of the Zacks research report on Pharma Mar (PHMMF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Pharma Mar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharma Mar and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply